Strauss Borrelli PLLC, a leading data breach law firm, is investigating Resolian, Inc., formerly Alliance Pharma Inc. and Drug Development Solutions Ltd., regarding its recent data breach. The Resolian data breach involved sensitive personal identifiable information belonging to an undetermined number of individuals.
ABOUT RESOLIAN, INC. FORMERLY ALLIANCE PHARMA INC. AND DRUG DEVELOPMENT SOLUTIONS LTD.:
Resolian is a pharmaceutical company and global research laboratory based in Pennsylvania. Founded in 2008, Resolian provides specialized services in GxP and nonregulated bioanalysis, drug metabolism/pharmacokinetics (DMPK), and GMP CMC analytical and materials science.2 Today, Resolian’s global bioanalytics division has an extensive track record across therapeutic modalities and biological matrices, including conventional small molecules, peptides, large proteins and antibodies, antibody-drug conjugates, and oligonucleotides.3 Additionally, Resolian’s dedicated analytical sciences division has over two decades of experience solving the most complex challenges in testing raw materials, formulated products, packaging and medical devices for trace impurities, contamination, degradation and quality control.3 Headquartered in Malvern, Pennsylvania, Resolian has additional locations in the United Kingdom, China, and Australia, and employs over 500 individuals.
WHAT HAPPENED?
Recently, Resolian reported to the Attorney General of the Commonwealth Massachusetts that it had experienced a data breach in which the sensitive personal identifiable information in its systems may have been accessed. According to the breach notice, Resolian recently discovered suspicious activity within certain company email accounts. As a result, Resolian launched an investigation to determine the nature of the incident.
Through its investigation, Resolian learned that sensitive personal information may have been viewed through these email accounts. As a result, Resolian began a review of the data to determine what information had been impacted as well as identify the specific individuals affected. While the information impacted varies depending on the individual, the type of information potentially exposed includes:
- Name
- Social Security number
- Username and password
On July 29, 2024, Resolian began mailing data breach notification letters to impacted individuals. Based on the breach notice sent to Massachusetts residents, Resolian is providing affected individuals with a list of the specific type of sensitive information impacted and 24 months of complimentary credit monitoring services. A link to the form breach notification letter that Resolian filed with the Attorney General of the Commonwealth of Massachusetts is below.
If you received a breach notification letter from Resolian, Inc. formerly Alliance Pharma Inc. and Drug Development Solutions Ltd.:
We would like to speak with you about your rights and potential legal remedies in response to this data breach. Please fill out the form, below, or contact us at 872.263.1100 or sam@straussborrelli.com.
